Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats : A model for cytoprotective studies

A superior effectiveness in various lesion assays was noted for the novel pentadecapeptide BPC 157, originated from human gastric juice protein (BPC) and claimed to be a cytoprotective agent. From this viewpoint, as a previously untreated experimental improvement to create an acid-free environmental...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Digestive diseases and sciences 1997-05, Vol.42 (5), p.1029-1037
Hauptverfasser: SIKIRIC, P, MIKUS, D, ZORICIC, I, PERIC, J, KONJEVODA, P, PEROVIC, D, JURINA, L, HANZEVACKI, M, SEPAROVIC, J, GJURASIN, M, JADRIJEVIC, S, JELOVAC, N, SEIWERTH, S, MIKLIC, P, BULJAT, G, MAROVIC, A, GRABAREVIC, Z, RUCMAN, R, PETEK, M, JAGIC, V, TURKOVIC, B, ROTKVIC, I, MISE, S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1037
container_issue 5
container_start_page 1029
container_title Digestive diseases and sciences
container_volume 42
creator SIKIRIC, P
MIKUS, D
ZORICIC, I
PERIC, J
KONJEVODA, P
PEROVIC, D
JURINA, L
HANZEVACKI, M
SEPAROVIC, J
GJURASIN, M
JADRIJEVIC, S
JELOVAC, N
SEIWERTH, S
MIKLIC, P
BULJAT, G
MAROVIC, A
GRABAREVIC, Z
RUCMAN, R
PETEK, M
JAGIC, V
TURKOVIC, B
ROTKVIC, I
MISE, S
description A superior effectiveness in various lesion assays was noted for the novel pentadecapeptide BPC 157, originated from human gastric juice protein (BPC) and claimed to be a cytoprotective agent. From this viewpoint, as a previously untreated experimental improvement to create an acid-free environmental for cytoprotection studies, total gastrectomy was done 24 hr before the ulcerogenic procedure. In the absence of stomach and gastric acid, the damaging effects of cysteamine (400 mg/kg subcutaneously, death 24 hr thereafter), to date thought to be an acid-related duodenal ulcerogen, and the BPC 157 cytoprotective effect (10 microg or 10 ng/kg intraperitoneally) were further challenged. BPC 157 was compared with reference agents [cimetidine (50), ranitidine (10), omeprazole (10), bromocriptine (10) and atropine (10) (mg/kg intraperitoneally, 1 hr before cysteamine] known to be also cytoprotective. In naive rats, with intact stomach, all of them showed a strong beneficial effect. Interestingly, in gastrectomized animals, the application of BPC 157 or the reference agents before cysteamine significantly prevented the otherwise severe duodenal lesion development noted in the control gastrectomized cysteamine rats. In groups without cysteamine, no lesions were noted (laparotomy, gastrectomy only, 24 or 48 hr postsurgical period), nor was lesion potentiation seen in cysteamine-treated laparotomized animals. In summary, these findings--equal damaging effect of cysteamine and equal protection of pentadecapeptide BPC 157 and reference agents in gastrectomized and rats with intact stomach--seem to be particularly relevant for a cytoprotective viewpoint. Without a stomach, the cysteamine damaging effect was convincingly defined as an essential gastric acid-independent injury (analogous to ethanol gastric lesions). Likewise, a high "cytoprotective capacity," apparently acid independent, common for all tested agents (novel pentadecapeptide BPC 157, cimetidine, ranitidine, omeprazole and atropine) could be clearly stressed.
doi_str_mv 10.1023/A:1018893220943
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_214338137</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>404185571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c308t-35a220a4a29c7a852df592fe9e5c188c24b7a3cabbb50f61af51ed6beaa312493</originalsourceid><addsrcrecordid>eNo9kE9vFDEMxSMEKtvCmRNShDh2IX8mM5PelhWllSq1BzivPImDUs1MhiRbaful-Ip4xcLJ9vNPz9Zj7J0Un6RQ-vPmSgrZ91YrJWyjX7CVNJ1eK9P2L9lKyJZ6KdvX7LyURyGE7WR7xs6sbKww_Yr9fsC5gkcHCy41euRfHracPC65ixOSEme85Bnm-K8fcpqSy5Hw4wiz51BzWmjiGAK6yuPM3aFUhOkojlhimstRranCOB74Tyg1E0lW8Rk9-dfCr_iGT8njyEPKZFDTklMlKj4hL3XvI5Y37FWAseDbU71gP66_ft_erO_uv91uN3drp0Vf19oABQINKOs66I3ywVgV0KJxFJdTzdCBdjAMgxGhlRCMRN8OCKClaqy-YB_--tILv_ZY6u4x7fNMJ3dKNlr3UncEvT9B-2FCv1tynCAfdqd0af_xtIfiYAyUoovlP6batmuU0n8AVr2MHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214338137</pqid></control><display><type>article</type><title>Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats : A model for cytoprotective studies</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>SIKIRIC, P ; MIKUS, D ; ZORICIC, I ; PERIC, J ; KONJEVODA, P ; PEROVIC, D ; JURINA, L ; HANZEVACKI, M ; SEPAROVIC, J ; GJURASIN, M ; JADRIJEVIC, S ; JELOVAC, N ; SEIWERTH, S ; MIKLIC, P ; BULJAT, G ; MAROVIC, A ; GRABAREVIC, Z ; RUCMAN, R ; PETEK, M ; JAGIC, V ; TURKOVIC, B ; ROTKVIC, I ; MISE, S</creator><creatorcontrib>SIKIRIC, P ; MIKUS, D ; ZORICIC, I ; PERIC, J ; KONJEVODA, P ; PEROVIC, D ; JURINA, L ; HANZEVACKI, M ; SEPAROVIC, J ; GJURASIN, M ; JADRIJEVIC, S ; JELOVAC, N ; SEIWERTH, S ; MIKLIC, P ; BULJAT, G ; MAROVIC, A ; GRABAREVIC, Z ; RUCMAN, R ; PETEK, M ; JAGIC, V ; TURKOVIC, B ; ROTKVIC, I ; MISE, S</creatorcontrib><description>A superior effectiveness in various lesion assays was noted for the novel pentadecapeptide BPC 157, originated from human gastric juice protein (BPC) and claimed to be a cytoprotective agent. From this viewpoint, as a previously untreated experimental improvement to create an acid-free environmental for cytoprotection studies, total gastrectomy was done 24 hr before the ulcerogenic procedure. In the absence of stomach and gastric acid, the damaging effects of cysteamine (400 mg/kg subcutaneously, death 24 hr thereafter), to date thought to be an acid-related duodenal ulcerogen, and the BPC 157 cytoprotective effect (10 microg or 10 ng/kg intraperitoneally) were further challenged. BPC 157 was compared with reference agents [cimetidine (50), ranitidine (10), omeprazole (10), bromocriptine (10) and atropine (10) (mg/kg intraperitoneally, 1 hr before cysteamine] known to be also cytoprotective. In naive rats, with intact stomach, all of them showed a strong beneficial effect. Interestingly, in gastrectomized animals, the application of BPC 157 or the reference agents before cysteamine significantly prevented the otherwise severe duodenal lesion development noted in the control gastrectomized cysteamine rats. In groups without cysteamine, no lesions were noted (laparotomy, gastrectomy only, 24 or 48 hr postsurgical period), nor was lesion potentiation seen in cysteamine-treated laparotomized animals. In summary, these findings--equal damaging effect of cysteamine and equal protection of pentadecapeptide BPC 157 and reference agents in gastrectomized and rats with intact stomach--seem to be particularly relevant for a cytoprotective viewpoint. Without a stomach, the cysteamine damaging effect was convincingly defined as an essential gastric acid-independent injury (analogous to ethanol gastric lesions). Likewise, a high "cytoprotective capacity," apparently acid independent, common for all tested agents (novel pentadecapeptide BPC 157, cimetidine, ranitidine, omeprazole and atropine) could be clearly stressed.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1023/A:1018893220943</identifier><identifier>PMID: 9149058</identifier><identifier>CODEN: DDSCDJ</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Animals ; Anti-Ulcer Agents - pharmacology ; Atropine - pharmacology ; Biological and medical sciences ; Bromocriptine - pharmacology ; Cimetidine - pharmacology ; Cysteamine - toxicity ; Digestive system ; Duodenal Ulcer - chemically induced ; Duodenal Ulcer - prevention &amp; control ; Female ; Gastrectomy ; Medical sciences ; Omeprazole - pharmacology ; Peptide Fragments - pharmacology ; Pharmacology. Drug treatments ; Proteins - pharmacology ; Ranitidine - pharmacology ; Rats ; Rats, Wistar</subject><ispartof>Digestive diseases and sciences, 1997-05, Vol.42 (5), p.1029-1037</ispartof><rights>1997 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers May 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c308t-35a220a4a29c7a852df592fe9e5c188c24b7a3cabbb50f61af51ed6beaa312493</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2667422$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9149058$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SIKIRIC, P</creatorcontrib><creatorcontrib>MIKUS, D</creatorcontrib><creatorcontrib>ZORICIC, I</creatorcontrib><creatorcontrib>PERIC, J</creatorcontrib><creatorcontrib>KONJEVODA, P</creatorcontrib><creatorcontrib>PEROVIC, D</creatorcontrib><creatorcontrib>JURINA, L</creatorcontrib><creatorcontrib>HANZEVACKI, M</creatorcontrib><creatorcontrib>SEPAROVIC, J</creatorcontrib><creatorcontrib>GJURASIN, M</creatorcontrib><creatorcontrib>JADRIJEVIC, S</creatorcontrib><creatorcontrib>JELOVAC, N</creatorcontrib><creatorcontrib>SEIWERTH, S</creatorcontrib><creatorcontrib>MIKLIC, P</creatorcontrib><creatorcontrib>BULJAT, G</creatorcontrib><creatorcontrib>MAROVIC, A</creatorcontrib><creatorcontrib>GRABAREVIC, Z</creatorcontrib><creatorcontrib>RUCMAN, R</creatorcontrib><creatorcontrib>PETEK, M</creatorcontrib><creatorcontrib>JAGIC, V</creatorcontrib><creatorcontrib>TURKOVIC, B</creatorcontrib><creatorcontrib>ROTKVIC, I</creatorcontrib><creatorcontrib>MISE, S</creatorcontrib><title>Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats : A model for cytoprotective studies</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><description>A superior effectiveness in various lesion assays was noted for the novel pentadecapeptide BPC 157, originated from human gastric juice protein (BPC) and claimed to be a cytoprotective agent. From this viewpoint, as a previously untreated experimental improvement to create an acid-free environmental for cytoprotection studies, total gastrectomy was done 24 hr before the ulcerogenic procedure. In the absence of stomach and gastric acid, the damaging effects of cysteamine (400 mg/kg subcutaneously, death 24 hr thereafter), to date thought to be an acid-related duodenal ulcerogen, and the BPC 157 cytoprotective effect (10 microg or 10 ng/kg intraperitoneally) were further challenged. BPC 157 was compared with reference agents [cimetidine (50), ranitidine (10), omeprazole (10), bromocriptine (10) and atropine (10) (mg/kg intraperitoneally, 1 hr before cysteamine] known to be also cytoprotective. In naive rats, with intact stomach, all of them showed a strong beneficial effect. Interestingly, in gastrectomized animals, the application of BPC 157 or the reference agents before cysteamine significantly prevented the otherwise severe duodenal lesion development noted in the control gastrectomized cysteamine rats. In groups without cysteamine, no lesions were noted (laparotomy, gastrectomy only, 24 or 48 hr postsurgical period), nor was lesion potentiation seen in cysteamine-treated laparotomized animals. In summary, these findings--equal damaging effect of cysteamine and equal protection of pentadecapeptide BPC 157 and reference agents in gastrectomized and rats with intact stomach--seem to be particularly relevant for a cytoprotective viewpoint. Without a stomach, the cysteamine damaging effect was convincingly defined as an essential gastric acid-independent injury (analogous to ethanol gastric lesions). Likewise, a high "cytoprotective capacity," apparently acid independent, common for all tested agents (novel pentadecapeptide BPC 157, cimetidine, ranitidine, omeprazole and atropine) could be clearly stressed.</description><subject>Animals</subject><subject>Anti-Ulcer Agents - pharmacology</subject><subject>Atropine - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Bromocriptine - pharmacology</subject><subject>Cimetidine - pharmacology</subject><subject>Cysteamine - toxicity</subject><subject>Digestive system</subject><subject>Duodenal Ulcer - chemically induced</subject><subject>Duodenal Ulcer - prevention &amp; control</subject><subject>Female</subject><subject>Gastrectomy</subject><subject>Medical sciences</subject><subject>Omeprazole - pharmacology</subject><subject>Peptide Fragments - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Proteins - pharmacology</subject><subject>Ranitidine - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNo9kE9vFDEMxSMEKtvCmRNShDh2IX8mM5PelhWllSq1BzivPImDUs1MhiRbaful-Ip4xcLJ9vNPz9Zj7J0Un6RQ-vPmSgrZ91YrJWyjX7CVNJ1eK9P2L9lKyJZ6KdvX7LyURyGE7WR7xs6sbKww_Yr9fsC5gkcHCy41euRfHracPC65ixOSEme85Bnm-K8fcpqSy5Hw4wiz51BzWmjiGAK6yuPM3aFUhOkojlhimstRranCOB74Tyg1E0lW8Rk9-dfCr_iGT8njyEPKZFDTklMlKj4hL3XvI5Y37FWAseDbU71gP66_ft_erO_uv91uN3drp0Vf19oABQINKOs66I3ywVgV0KJxFJdTzdCBdjAMgxGhlRCMRN8OCKClaqy-YB_--tILv_ZY6u4x7fNMJ3dKNlr3UncEvT9B-2FCv1tynCAfdqd0af_xtIfiYAyUoovlP6batmuU0n8AVr2MHg</recordid><startdate>19970501</startdate><enddate>19970501</enddate><creator>SIKIRIC, P</creator><creator>MIKUS, D</creator><creator>ZORICIC, I</creator><creator>PERIC, J</creator><creator>KONJEVODA, P</creator><creator>PEROVIC, D</creator><creator>JURINA, L</creator><creator>HANZEVACKI, M</creator><creator>SEPAROVIC, J</creator><creator>GJURASIN, M</creator><creator>JADRIJEVIC, S</creator><creator>JELOVAC, N</creator><creator>SEIWERTH, S</creator><creator>MIKLIC, P</creator><creator>BULJAT, G</creator><creator>MAROVIC, A</creator><creator>GRABAREVIC, Z</creator><creator>RUCMAN, R</creator><creator>PETEK, M</creator><creator>JAGIC, V</creator><creator>TURKOVIC, B</creator><creator>ROTKVIC, I</creator><creator>MISE, S</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>19970501</creationdate><title>Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats : A model for cytoprotective studies</title><author>SIKIRIC, P ; MIKUS, D ; ZORICIC, I ; PERIC, J ; KONJEVODA, P ; PEROVIC, D ; JURINA, L ; HANZEVACKI, M ; SEPAROVIC, J ; GJURASIN, M ; JADRIJEVIC, S ; JELOVAC, N ; SEIWERTH, S ; MIKLIC, P ; BULJAT, G ; MAROVIC, A ; GRABAREVIC, Z ; RUCMAN, R ; PETEK, M ; JAGIC, V ; TURKOVIC, B ; ROTKVIC, I ; MISE, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c308t-35a220a4a29c7a852df592fe9e5c188c24b7a3cabbb50f61af51ed6beaa312493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Animals</topic><topic>Anti-Ulcer Agents - pharmacology</topic><topic>Atropine - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Bromocriptine - pharmacology</topic><topic>Cimetidine - pharmacology</topic><topic>Cysteamine - toxicity</topic><topic>Digestive system</topic><topic>Duodenal Ulcer - chemically induced</topic><topic>Duodenal Ulcer - prevention &amp; control</topic><topic>Female</topic><topic>Gastrectomy</topic><topic>Medical sciences</topic><topic>Omeprazole - pharmacology</topic><topic>Peptide Fragments - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Proteins - pharmacology</topic><topic>Ranitidine - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SIKIRIC, P</creatorcontrib><creatorcontrib>MIKUS, D</creatorcontrib><creatorcontrib>ZORICIC, I</creatorcontrib><creatorcontrib>PERIC, J</creatorcontrib><creatorcontrib>KONJEVODA, P</creatorcontrib><creatorcontrib>PEROVIC, D</creatorcontrib><creatorcontrib>JURINA, L</creatorcontrib><creatorcontrib>HANZEVACKI, M</creatorcontrib><creatorcontrib>SEPAROVIC, J</creatorcontrib><creatorcontrib>GJURASIN, M</creatorcontrib><creatorcontrib>JADRIJEVIC, S</creatorcontrib><creatorcontrib>JELOVAC, N</creatorcontrib><creatorcontrib>SEIWERTH, S</creatorcontrib><creatorcontrib>MIKLIC, P</creatorcontrib><creatorcontrib>BULJAT, G</creatorcontrib><creatorcontrib>MAROVIC, A</creatorcontrib><creatorcontrib>GRABAREVIC, Z</creatorcontrib><creatorcontrib>RUCMAN, R</creatorcontrib><creatorcontrib>PETEK, M</creatorcontrib><creatorcontrib>JAGIC, V</creatorcontrib><creatorcontrib>TURKOVIC, B</creatorcontrib><creatorcontrib>ROTKVIC, I</creatorcontrib><creatorcontrib>MISE, S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SIKIRIC, P</au><au>MIKUS, D</au><au>ZORICIC, I</au><au>PERIC, J</au><au>KONJEVODA, P</au><au>PEROVIC, D</au><au>JURINA, L</au><au>HANZEVACKI, M</au><au>SEPAROVIC, J</au><au>GJURASIN, M</au><au>JADRIJEVIC, S</au><au>JELOVAC, N</au><au>SEIWERTH, S</au><au>MIKLIC, P</au><au>BULJAT, G</au><au>MAROVIC, A</au><au>GRABAREVIC, Z</au><au>RUCMAN, R</au><au>PETEK, M</au><au>JAGIC, V</au><au>TURKOVIC, B</au><au>ROTKVIC, I</au><au>MISE, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats : A model for cytoprotective studies</atitle><jtitle>Digestive diseases and sciences</jtitle><addtitle>Dig Dis Sci</addtitle><date>1997-05-01</date><risdate>1997</risdate><volume>42</volume><issue>5</issue><spage>1029</spage><epage>1037</epage><pages>1029-1037</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><coden>DDSCDJ</coden><abstract>A superior effectiveness in various lesion assays was noted for the novel pentadecapeptide BPC 157, originated from human gastric juice protein (BPC) and claimed to be a cytoprotective agent. From this viewpoint, as a previously untreated experimental improvement to create an acid-free environmental for cytoprotection studies, total gastrectomy was done 24 hr before the ulcerogenic procedure. In the absence of stomach and gastric acid, the damaging effects of cysteamine (400 mg/kg subcutaneously, death 24 hr thereafter), to date thought to be an acid-related duodenal ulcerogen, and the BPC 157 cytoprotective effect (10 microg or 10 ng/kg intraperitoneally) were further challenged. BPC 157 was compared with reference agents [cimetidine (50), ranitidine (10), omeprazole (10), bromocriptine (10) and atropine (10) (mg/kg intraperitoneally, 1 hr before cysteamine] known to be also cytoprotective. In naive rats, with intact stomach, all of them showed a strong beneficial effect. Interestingly, in gastrectomized animals, the application of BPC 157 or the reference agents before cysteamine significantly prevented the otherwise severe duodenal lesion development noted in the control gastrectomized cysteamine rats. In groups without cysteamine, no lesions were noted (laparotomy, gastrectomy only, 24 or 48 hr postsurgical period), nor was lesion potentiation seen in cysteamine-treated laparotomized animals. In summary, these findings--equal damaging effect of cysteamine and equal protection of pentadecapeptide BPC 157 and reference agents in gastrectomized and rats with intact stomach--seem to be particularly relevant for a cytoprotective viewpoint. Without a stomach, the cysteamine damaging effect was convincingly defined as an essential gastric acid-independent injury (analogous to ethanol gastric lesions). Likewise, a high "cytoprotective capacity," apparently acid independent, common for all tested agents (novel pentadecapeptide BPC 157, cimetidine, ranitidine, omeprazole and atropine) could be clearly stressed.</abstract><cop>Heidelberg</cop><pub>Springer</pub><pmid>9149058</pmid><doi>10.1023/A:1018893220943</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0163-2116
ispartof Digestive diseases and sciences, 1997-05, Vol.42 (5), p.1029-1037
issn 0163-2116
1573-2568
language eng
recordid cdi_proquest_journals_214338137
source MEDLINE; SpringerLink Journals
subjects Animals
Anti-Ulcer Agents - pharmacology
Atropine - pharmacology
Biological and medical sciences
Bromocriptine - pharmacology
Cimetidine - pharmacology
Cysteamine - toxicity
Digestive system
Duodenal Ulcer - chemically induced
Duodenal Ulcer - prevention & control
Female
Gastrectomy
Medical sciences
Omeprazole - pharmacology
Peptide Fragments - pharmacology
Pharmacology. Drug treatments
Proteins - pharmacology
Ranitidine - pharmacology
Rats
Rats, Wistar
title Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats : A model for cytoprotective studies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T07%3A29%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pentadecapeptide%20BPC%20157,%20cimetidine,%20ranitidine,%20bromocriptine,%20and%20atropine%20effect%20in%20cysteamine%20lesions%20in%20totally%20gastrectromized%20rats%20:%20A%20model%20for%20cytoprotective%20studies&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=SIKIRIC,%20P&rft.date=1997-05-01&rft.volume=42&rft.issue=5&rft.spage=1029&rft.epage=1037&rft.pages=1029-1037&rft.issn=0163-2116&rft.eissn=1573-2568&rft.coden=DDSCDJ&rft_id=info:doi/10.1023/A:1018893220943&rft_dat=%3Cproquest_pubme%3E404185571%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=214338137&rft_id=info:pmid/9149058&rfr_iscdi=true